Search clinical trials for: 14C-BI 409306

Total 3888 results

Boehringer Ingelheim

Completed

Metabolism and Pharmacokinetics of [14C]-BI 409306 After Administration as Oral Solution in Healthy Male Volunteers

Healthy

United Kingdom
Boehringer Ingelheim

Completed

A Study to Investigate the Efficacy, Safety and Tolerability of Four Different Doses of BI 409306 Compared to Placebo Given for 12 Weeks in Patients With Schizophrenia on Stable Antipsychotic Treatment.

Schizophrenia

United States, Taiwan, Germany, Japan, Canada
Boehringer Ingelheim

Completed

Study of Systemic and Ocular Safety and Pharmacokinetics of BI 409306 in Patients With Schizophrenia, Alzheimer's Disease, and Healthy Volunteers

Schizophrenia | Alzheimer Disease

United States
Boehringer Ingelheim

Completed

This Study in Healthy Men and Women Tests How the Body Takes up BI 409306

Healthy

Germany
Hoffmann-La Roche

Completed

Mass Balance and Absolute Bioavailability Study of RO7049389 in Healthy Volunteers

Healthy Volunteers

United Kingdom
Boehringer Ingelheim

Completed

A Study in Healthy Men to Test How BI 1291583 is Taken up by the Body

Healthy

Netherlands
Boehringer Ingelheim

Completed

Pharmacokinetics of BI 409306 After a High Fat, High Caloric Meal and After a Single Oral Dose Given at Bed Time in Healthy Volunteers

Healthy

Germany
Boehringer Ingelheim

Completed

Safety and Tolerability of BI 409306 in Patients With Schizophrenia

Schizophrenia

United States
Boehringer Ingelheim

Completed

Safety, Tolerability and Pharmacokinetics of BI 409306 Tablets in Healthy Asian Male Volunteers

Healthy

Korea, Republic of
Boehringer Ingelheim

Completed

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Rising Doses of BI 409306

Healthy

Germany
Boehringer Ingelheim

Completed

BI 409306 Cardiac Safety Trial in Healthy Volunteers

Healthy

Germany
Boehringer Ingelheim

Completed

Assessment of Exposure of BI 409306 in Cerebrospinal Fluid (CSF) Relative to Plasma as Well as to Evaluation of the Effect of Different Doses of BI 409306 on the cGMP (Cyclic Guanosine Monophosphate) Levels in CSF in Healthy Male Volunteers

Healthy

Belgium
Boehringer Ingelheim

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Doses

Healthy

Germany
Boehringer Ingelheim

Completed

This Study Tests BI 1467335 in Healthy Male Volunteers. The Study Tests How Different Doses of BI 1467335 Are Taken up and Handled by the Body

Healthy

Netherlands
Boehringer Ingelheim

Completed

Alzheimer Disease Proof of Concept Study With BI 409306 Versus Placebo

Alzheimer Disease

United States, Spain, Canada, United Kingdom, Germany, Italy, Netherlands, Portugal, Austria, Belgium, France, Poland
Boehringer Ingelheim

Completed

This Study in Healthy Men and Women Tests Whether BI 409306 Has an Effect on the ECG (Thorough QT Study)

Healthy

Germany
Boehringer Ingelheim

Completed

A Study in Healthy Men to Test How BI 1358894 is Taken up and Handled by the Body

Healthy

Netherlands
Boehringer Ingelheim

Terminated

This Study Tests Whether BI 409306 Prevents Patients With a Specific Type of Mental Illness (Attenuated Psychosis Syndrome) From Becoming Worse. This Study Looks at How Well Patients Tolerate the Medicine and How Effective it is Over 1 Year

Psychotic Disorders

United States, Canada, United Kingdom, China
Boehringer Ingelheim

Completed

Safety Tolerability and Pharmacokinetic of BI 409306

Healthy

Germany
Boehringer Ingelheim

Completed

Olmutinib (BI 1482694) ADME Study

Healthy

Netherlands
Vivozon, Inc.

Completed

Absorption, Metabolism, Excretion, and Mass Balance Study of [14C]-VVZ-149 in Healthy Adult Male Subjects

Healthy Adult Male

United States
Rachel Lieberman

Terminated

Capsular Tension Rings in Intraocular Lens Rotation

Cataract | Ophthalmoplegia | Ophthalmologic Complication

United States
Boehringer Ingelheim

Completed

Metabolism and Pharmacokinetics of Oral Solution of [14C]-BI 201335 in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Terminated

This Study Tests Whether BI 409306 Prevents Patients With Schizophrenia From Becoming Worse. This Study Looks at How Well Patients Tolerate BI 409306 and How Effective it is Over 6 Months

Schizophrenia

United States, Korea, Republic of, Canada, Japan, Spain, Taiwan, France
Boehringer Ingelheim

Completed

A Study in Healthy Men to Test How BI 1015550 is Taken up and Handled by the Body

Healthy

Netherlands
Boehringer Ingelheim

Completed

A Study in Healthy Men to Test How BI 690517 is Taken up and Handled by the Body

Healthy

Netherlands
Boehringer Ingelheim

Completed

A Study in Healthy Men to Measure the Amount of BI 730357 in the Blood When Taken as a Tablet

Healthy

Netherlands
Boehringer Ingelheim

Completed

A Study in Healthy Men to Find Out How BI 1015550 is Taken up and Handled by the Body

Healthy

Netherlands
Boehringer Ingelheim

Completed

A Study in Healthy Men to Test How BI 1810631 is Taken up and Processed by the Body

Healthy

Netherlands
Boehringer Ingelheim

Completed

A Study in Healthy Men to Test How BI 456906 is Processed in the Body

Healthy

Netherlands
Boehringer Ingelheim

Completed

A Study in Healthy Men to Measure the Amount of BI 425809 in the Blood When Taken as a Tablet

Healthy

Netherlands
Taisho Pharmaceutical Co., Ltd.

Completed

Mass Balance Study of TS-142 in Healthy Adult Subjects.

Healthy Male Subjects

Japan
Boehringer Ingelheim

Completed

BI 409306 in Patients With Cognitive Impairment Due to Alzheimer's Disease.

Alzheimer Disease

United States, Canada, United Kingdom, Germany, Portugal, France, Belgium, Netherlands, Austria, Poland, Italy
Hoffmann-La Roche

Completed

A Study to Determine the Excretion Balance, Pharmacokinetics, Metabolism and Absolute Oral Bioavailability of a Single Oral Dose of [14C]-Labeled Idasanutlin and an Intravenous Tracer Dose of [13C]-Labeled Idasanutlin in a Single Cohort of Participants With Solid Tumors (Malignancies)

Solid Tumors

Hungary
Boehringer Ingelheim

Completed

A Study in Healthy Men to Test How BI 764198 is Processed in the Body

Healthy

Netherlands
Boehringer Ingelheim

Completed

This Study in Healthy Men Tests How the Body Takes up BI 1467335

Healthy

Netherlands
Boehringer Ingelheim

Completed

A Study in Healthy Men to Test How BI 1291583 is Processed in the Body

Healthy

Netherlands
Boehringer Ingelheim

Completed

A Study in Healthy Men to Test How BI 730357 is Processed by the Body

Healthy

Netherlands
Boehringer Ingelheim

Completed

Investigation of Pharmacokinetic Drug-drug Interaction of BI 409306 and Donepezil in Healthy Male and Female Subjects

Healthy

Germany
National Cancer Institute (NCI)

Completed

Obatoclax Mesylate and Topotecan Hydrochloride in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer or Advanced Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific | Recurrent Small Cell Lung Cancer

United States
Boehringer Ingelheim

Completed

A Study in Healthy Men to Find Out How BI 425809 is Taken up and Handled by the Body

Healthy

Netherlands
Boehringer Ingelheim

Completed

Drug Drug Interaction Trial With Strong CYP3A4 Inhibitor (Itraconazole) in CYP2C19 Extensive Metabolizers and Poor Metabolizers

Healthy

Korea, Republic of
Boehringer Ingelheim

Completed

Investigation of the Metabolism and Pharmacokinetics of 10 mg [14C] BI 1356 Administered Orally Compared to 5 mg [14C] BI 1356 Administered Intravenously in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

A Study in Healthy Men to Test if Taking Different Formulations of BI 1358894 With or Without Food Influences the Amount of BI 1358894 in the Blood

Healthy

Germany
Boehringer Ingelheim

Recruiting

A Study to Test How BI 765063 and BI 770371 Are Taken up in Tumours of People With Different Types of Advanced Cancer Who Are Also Taking Ezabenlimab

Melanoma | Non-small Cell Lung Cancer (NSCLC) | Carcinoma, Squamous Cell of Head and Neck (HNSCC)

Netherlands
Boehringer Ingelheim

Not yet recruiting

A Study in People With Overweight or Obesity to Test How BI 1820237, BI 456906, or a Combination of Both Affects Brain Activity

Obesity
Boehringer Ingelheim

Completed

This Study in Healthy Men Tests How Different Doses of BI 1358894 Are Taken up in the Body and How Well They Are Tolerated. The Study Also Looks at How Food Influences the Amount of BI 1358894 in the Blood

Healthy

Germany
Boehringer Ingelheim

Withdrawn

A Study to Test BI 754091 Alone or in Combination With BI 836880 in People Who Have Advanced Anal Cancer

Anal Canal Squamous Cell Carcinoma

Korea, Republic of
Boehringer Ingelheim

Recruiting

A Study in People With Advanced Cancer to Test How BI 907828 is Processed in the Body

Solid Tumors

Hungary
Boehringer Ingelheim

Terminated

A Study in Healthy Men to Find the Best Formulation of BI 894416 and to Test How This is Taken up in the Body

Healthy

United Kingdom

3

Subscribe